Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
05 Mars 2024 - 10:30PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
that preclinical data from CB-012, an allogeneic anti-CLL-1 CAR-T
cell therapy for the treatment of relapsed or refractory acute
myeloid leukemia (r/r AML), will be presented as a poster at the
upcoming American Association for Cancer Research (AACR) Annual
Meeting 2024, held April 5-10, 2024 in San Diego.
Details of the poster presentation are as follows:
Title: Preclinical evaluation of CB-012, an
allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific
and potent cytotoxicity in acute myeloid leukemia (AML) xenograft
modelsPresenter: Brian Francica, PhDDate
and time: Tuesday, April 9, 2024, 1:30 - 5:00 pm
PTSession: Adoptive Cellular Therapy
2Location: San Diego Convention Center, poster
section 40, poster board 14Abstract number:
6323
The poster will be available on the Scientific Publications page
of Caribou’s website on Tuesday, April 9, 2024 at 1:30 pm PT.
About CB-012CB-012 is a product candidate from
Caribou’s allogeneic CAR-T cell therapy platform being evaluated in
the AMpLify Phase 1 clinical trial in patients with relapsed or
refractory acute myeloid leukemia (r/r AML). CB-012 is an
anti-CLL-1 CAR-T cell therapy engineered with five genome edits,
enabled by Caribou’s patented next-generation CRISPR technology
platform, which uses Cas12a chRDNA genome editing to significantly
improve the specificity of genome edits. To Caribou’s knowledge,
CB-012 is the first allogeneic CAR-T cell therapy with both
checkpoint disruption, through a PD-1 knockout, and immune
cloaking, through a B2M knockout and B2M–HLA-E fusion protein
insertion; both armoring strategies are designed to improve
antitumor activity. Additional information on the AMpLify trial
(NCT06128044) can be found at clinicaltrials.gov.
About Caribou’s novel next-generation CRISPR
platform CRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its Cas12a chRDNA technology,
enables superior precision to develop cell therapies that are
armored to potentially improve antitumor activity. Caribou is
advancing a pipeline of off-the-shelf cell therapies from its CAR-T
and CAR-NK platforms as readily available treatments for patients
with hematologic malignancies and solid tumors. Follow us
@CaribouBio and visit www.cariboubio.com.
Forward-looking statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, without limitation, statements
related to Caribou’s strategy, plans, and objectives, and
expectations regarding its clinical and preclinical development
programs, including its expectations relating to the AMpLify Phase
1 clinical trial for CB-012. Management believes that these
forward-looking statements are reasonable as and when made.
However, such forward-looking statements are subject to risks and
uncertainties, and actual results may differ materially from any
future results expressed or implied by the forward-looking
statements. Risks and uncertainties include, without limitation,
risks inherent in the development of cell therapy products;
uncertainties related to the initiation, cost, timing, progress,
and results of Caribou’s current and future research and
development programs, preclinical studies, and clinical trials; and
the risk that initial, preliminary, or interim clinical trial data
will not ultimately be predictive of the safety and efficacy of
Caribou’s product candidates or that clinical outcomes may differ
as patient enrollment continues and as more patient data becomes
available; the risk that preclinical study results observed will
not be borne out in human patients or different conclusions or
considerations are reached once additional data have been received
and fully evaluated; the ability to obtain key regulatory input and
approvals as well as other risk factors described from time to time
in Caribou’s filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended
December 31, 2022 and subsequent filings. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. Except as required by law, Caribou undertakes no
obligation to update publicly any forward-looking statements for
any reason.
Caribou Biosciences, Inc.
contacts:Investors:Amy Figueroa,
CFAinvestor.relations@cariboubio.com
Media:Peggy Vorwald,
PhDmedia@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Caribou Biosciences (NASDAQ:CRBU)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024